Figure 2. The 64 enrolled patients with metastatic colorectal cancer included 28 who received 6 cycles of neoadjuvant chemotherapy/targeted therapy (dashed line) and 36 who received ≥7 cycles (solid line). (A) Progression-free survival. (B) Overall survival.